Captrust Financial Advisors Biogen Inc. Transaction History

Captrust Financial Advisors

$33 Billion
Q3 2024

A detailed history of Captrust Financial Advisors transactions in Biogen Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 6,494 shares of BIIB stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,494

Previous 7,309 11.15%

Holding current value

$1.03 Million

Previous $1.69 Million 25.74%

% of portfolio

0.0%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$189.07 - $236.8 $154,092 - $192,992	-815 Reduced 11.15%	6,494 $1.26 Million
Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $31,435 - $39,058	-165 Reduced 2.21%	7,309 $1.69 Million
Q1 2024 May 15, 2024	SELL	$212.02 - $267.71 $569,485 - $719,069	-2,686 Reduced 26.44%	7,474 $1.61 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $38,730 - $46,621	-174 Reduced 1.68%	10,160 $2.63 Million
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $191,748 - $216,418	-757 Reduced 6.83%	10,334 $2.66 Million
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $698,584 - $807,236	2,538 Added 29.67%	11,091 $3.16 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $59,778 - $68,115	-233 Reduced 2.65%	8,553 $2.38 Million
Q4 2022 Feb 15, 2023	BUY	$252.44 - $306.72 $259,508 - $315,308	1,028 Added 13.25%	8,786 $2.43 Million
Q3 2022 Nov 16, 2022	BUY	$194.69 - $268.46 $126,548 - $174,499	650 Added 9.14%	7,758 $2.07 Million
Q2 2022 Aug 23, 2022	BUY	$187.54 - $223.02 $1.28 Million - $1.52 Million	6,808 Added 2269.33%	7,108 $1.45 Million
Q2 2022 Aug 16, 2022	SELL	$187.54 - $223.02 $1.04 Million - $1.23 Million	-5,527 Reduced 94.85%	300 $61,000
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $167,804 - $211,425	-866 Reduced 12.94%	5,827 $1.23 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $21,048 - $27,050	94 Added 1.42%	6,693 $1.61 Million
Q3 2021 Nov 16, 2021	BUY	$282.99 - $369.05 $157,625 - $205,560	557 Added 9.22%	6,599 $1.87 Million
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $33,670 - $53,912	-130 Reduced 2.11%	6,042 $2.09 Million
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $245,136 - $287,191	1,009 Added 19.54%	6,172 $1.73 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $78,910 - $118,780	334 Added 6.92%	5,163 $1.26 Million
Q3 2020 Nov 17, 2020	SELL	$264.77 - $305.71 $84,726 - $97,827	-320 Reduced 6.21%	4,829 $1.38 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $270,558 - $358,307	1,046 Added 25.49%	5,149 $1.36 Million
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $45,166 - $57,294	-168 Reduced 3.93%	4,103 $1.2 Million
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $653,798 - $903,391	2,971 Added 228.54%	4,271 $1.26 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $4,566 - $5,121	21 Added 1.64%	1,300 $303,000
Q2 2019 Aug 13, 2019	SELL	$219.29 - $241.72 $23,244 - $25,622	-106 Reduced 7.65%	1,279 $299,000
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $89,717 - $140,329	-414 Reduced 23.01%	1,385 $327,000
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $42,889 - $54,323	154 Added 9.36%	1,799 $541,000
Q3 2018 Nov 15, 2018	BUY	$293.51 - $383.83 $378,921 - $495,524	1,291 Added 364.69%	1,645 $581,000
Q2 2018 Aug 13, 2018	SELL	$257.52 - $306.91 $59,229 - $70,589	-230 Reduced 39.38%	354 $103,000
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $59,569 - $84,251	229 Added 64.51%	584 $156,000
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $103,059 - $115,434	335 Added 1675.0%	355 $113,000
Q3 2017 Feb 16, 2018	BUY	$281.15 - $329.69 $5,623 - $6,593	20	20 $6,000

Others Institutions Holding BIIB

# of Institutions

1,036

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Biogen Inc. Transaction History